KaydedilenlerDerginizi ekleyin

Dergiler / European Journal of Biology / 2026 / Volume: 85 Issue: 2

Paraoxonase 1 Gene Polymorphism and Its Influence on Cardiovascular Threat in Type 2 Diabetes Mellitus

Apoorva Tiwari(Santosh Deemed to be University)0009-0003-6019-1216
Gunjan Uttam(Santosh Deemed to be University)0000-0002-7093-4381
Awantika Das(Santosh Deemed to be University)0009-0001-8956-4261
Ayushi Singh(Santosh Deemed to be University)0009-0004-9518-8049
Shuvojit Moulik(Santosh Deemed to be University)0000-0002-6495-8758
Sayfa
—
Yayın Tarihi
2026-06-12
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This approach offers a promising direction for future research and clinical practice.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Type 2 diabetes mellitus (T2DM) is often complicated by oxidative stress, lipid abnormalities, and a high cardiovascular disease burden.
📊
Temel Bulgular & Veri:This review aims to examine the effects of paraoxonase 1 ( PON1 ) gene polymorphisms and its antioxidant activity in relation to high-density lipoproteins and the risk of cardiovascular diseases, such as atherosclerosis and coronary artery disease, in patients with T2DM.
💡
Sonuç & Katkı:This approach offers a promising direction for future research and clinical practice.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Paraoxonase 1 · Type 2 diabetes mellitus · Polymorphism

Abstract

Type 2 diabetes mellitus (T2DM) is often complicated by oxidative stress, lipid abnormalities, and a high cardiovascular disease burden. This review aims to examine the effects of paraoxonase 1 ( PON1 ) gene polymorphisms and its antioxidant activity in relation to high-density lipoproteins and the risk of cardiovascular diseases, such as atherosclerosis and coronary artery disease, in patients with T2DM. The published literature was comprehensively reviewed, focusing on studies exploring genetic variants of PON1 , enzymatic activity levels, ethnic distribution, and their interaction with metabolic and environmental factors in diabetic populations. The findings consistently showed that reduced PON1 activity is a major determinant of vascular risk in T2DM. Genetic variations alter enzyme function: the R allele of Q192R enhances paraoxon hydrolysis but reduces the protection of low-density lipoproteins, whereas the M allele of L55M decreases protein stability and circulating concentration. These effects vary across populations, with significant ethnic differences in allele prevalence. Beyond genetics, lifestyle and dietary factors, such as intake of saturated fats or polyphenol-rich foods, modulate PON1 activity, highlighting important gene-environment interactions. PON1 polymorphisms play a pivotal role in shaping cardiovascular vulnerability in patients with T2DM. Measuring enzyme activity may serve as a more accurate predictor of cardiovascular disease risk than genotyping alone because it reflects both inherited and environmental influences. Integrating genetic profiling with personalised dietary, lifestyle, and therapeutic interventions may lead to more precise cardiovascular risk assessment and improved outcomes for patients with diabetes. This approach offers a promising direction for future research and clinical practice.

🔖

Bu Makaleye Atıf Yap

Tiwari, A., Uttam, G., Das, A., Singh, A., Moulik, S. (2026). Paraoxonase 1 Gene Polymorphism and Its Influence on Cardiovascular Threat in Type 2 Diabetes Mellitus. European Journal of Biology, Volume: 85 Issue: 2. https://doi.org/10.26650/EurJBiol.2026.1770831

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (61)

  1. Alizadeh A, Mahrooz A, Hashemisoteh MB, et al. Paraoxonase 1 (PON1) L55M among common variants in the coding region of the paraoxonase gene family may contribute to glycemic control in type 2 diabetes. Clin Chim Acta. 2018;484:406-412. doi: https://doi.org/10.1016/j.cca.2018.05.037 google scholar
  2. Allemann RK, Bargota RS, Akhtar M, et al. Structure–activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors. Bioorg Med Chem Lett. 2003;13(10):1623-1626. doi:https://doi.org/10.1016/S0960- 894X(03)00290-7 google scholar
  3. Annema W, von Eckardstein A. Dysfunctional high-density lipoproteins in coronary heart disease: Implications for diagnostics and therapy. Transl Res. 2016;173:30-57. doi:https://doi.org/10.1016/j.trsl.2016.02.008 google scholar
  4. Bult H, Guns PJ, Van Assche T, et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with preexisting atherosclerosis. Br J Pharmacol. 2008;153(3):508-516. doi:https://doi.org/10.1038/sj.bjp.0707585 google scholar
  5. Burrell LM, Patel SK, Wai B, et al. Association of ACE2 genetic variants with blood pressure, left ventricular mass and cardiac function in Caucasians with type 2 diabetes. Am J Hypertens. 2012;25(2):216-222. doi:https://doi.org/10.1038/ajh. 2011.188 google scholar
  6. Charpentier G, Rung J, Cauchi S, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41(10):1110-1115. google scholar
  7. Costa LG, Furlong CE, eds. Paraoxonase (PON1) in health and disease: Basic and clinical aspects. Springer; 2002. google scholar
  8. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochem Pharmacol. 2011;81(3):337-344. doi:https://doi.org/10.1016/j.atheroscle rosis.2018.11.004 google scholar
  9. Deng Z, Xiang H, Gao W. Significant association between paraoxonase 1 rs662 polymorphism and coronary heart disease: A meta-analysis in the Chinese population. Herz. 2020;45(4):347-355. google scholar
  10. Donaghue KC, Hofer SE, Bennetts B, et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications. 2006;20(5):322-328. doi:https://doi.org/10.1016/j.jdiacomp.2005. 08.008 google scholar
  11. Durrington PN, Bashir B, Soran H. Paraoxonase 1 and atherosclerosis. Front Cardiovasc Med. 2023;10:1065967. doi:https://doi.org/10.3389/fcvm.2023.1065967 google scholar
  12. Durrington PN, Younis NN, Soran H, et al. High-density lipoprotein impedes glycation of low-density lipoprotein. Diab Vasc Dis Res. 2013;10(2):152-160. doi:https://doi.org/10.1177/1479164112454309 google scholar
  13. Ebtehaj S, Gruppen EG, Parvizi M, Tietge UJ, Dullaart RP. The anti-inflammatory function of HDL is impaired in type 2 diabetes: Role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovasc Diabetol. 2017;16(1):132. doi:https://doi.org/10.1186/s12933-017-0613-8 google scholar
  14. Fernando S, Chiu KC, Chuang LM, et al. Association of paraoxonase 1 polymorphism with beta-cell function:A case of molecular heterosis. Pancreas. 2004;28(4):e96-103. doi:https://doi.org/10.1097/00006676-200405000-00021 google scholar
  15. Flekač M, Škrha J, Zidkova K, Lacinova Z, Hilgertova J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res. 2008;57(5):717-726. google scholar
  16. Furlong CE, Costa LG, Giordano G, et al. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology. 2013;307:115-122. doi:https://doi.org/10.1016/j.tox.2012.07.011 google scholar
  17. Furlong CE. Paraoxonases: an historical perspective. In: The paraoxonases: their function in disease development and xenobiotic metabolism. Dordrecht: Springer; 2008:3-31. google scholar
  18. Golzari MH, Hosseini S, Koohdani F, et al. The effect of eicosapentaenoic acid on the serum levels and enzymatic activity of paraoxonase 1 in the patients with type 2 diabetes mellitus. Acta Medica Iranica. 2017,7:486-495. google scholar
  19. Hill JA, Lobmeyer MT, Gong Y, et al. Synergistic polymorphisms of β1- and α2C-adrenergic receptors and influence on left ventricular ejection fraction response to β-blocker therapy in heart failure. Pharmacogenet Genomics. 2007;17(4):277-82. doi:https://doi.org/10.1097/FPC.0b013e3280105245 google scholar
  20. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. In: Paraoxonases in inflammation, infection, and toxicology. Springer; 2009:113-127. doi:https://doi.org/10.1007/978-1-60761-350-3_11 google scholar
  21. Jarvik GP, Kim DS, Burt AA, et al. Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res. 2013;54(2):552-560. doi:https://doi.org/10.1194/jlr.P033266 google scholar
  22. Kamerlin SC, Blaha-Nelson D, Kruger DM, et al. Active site hydrophobicity and the convergent evolution of paraoxonase activity in structurally divergent enzymes: the case of serum paraoxonase 1. J Am Chem Soc. 2017;139(3):1155-1167. doi:https://doi.org/10.1021/jacs.6b10801 google scholar
  23. Khersonsky O, Tawfik DS. Structure–reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005;44(16):6371-6382. google scholar
  24. Khuda F, Rahman N, Zakiullah, et al. Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) variants with myocardial infarction in the Pashtun ethnic population of Khyber Pakhtunkhwa, Pakistan. Genes (Basel). 2023;14(3):687. doi:https://doi.org/10.3390/genes14030687 google scholar
  25. Kimura S, Gugliucci A, Kinugasa E, et al. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med. 2011;49(1):61-67. doi:https://doi.org/10.1515/CCLM.2011.004 European Journal of Biology, 85 (2): 204–212 211 PON1 Polymorphism and cardiovascular disease risk in T2D | Tiwari et al., 2026 google scholar
  26. Korengluzer M, Aviram M, Meilin E, et al. The antioxidant HDL-associated paraoxonase1 (PON1) attenuates diabetes development and stimulates β-cell insulin release. Atherosclerosis. 2011;219(2):510-518. doi:https://doi.org/10.1016/ j.atherosclerosis.2011.07.119 google scholar
  27. Kunachowicz D, Ściskalska M, Kępińska M. Modulatory Effect of lifestyle-related environmental and genetic factors on paraoxonase1 activity: A review. Int J Environmental Res Public Health. 2023;20(4):2813. doi:https://www.mdpi.com/1660- 4601/20/4/2813 google scholar
  28. Lauro D, Andreadi A, Bellia A, et al. The molecular link between oxidative stress, insulin resistance and type 2 diabetes: A target for new therapies against cardiovascular diseases. Curr Opin Pharmacol. 2022;62:85-96. doi:https://doi. org/10.1016/j.coph.2021.11.010 google scholar
  29. Lazavi F, Mirmiran P, Sohrab G, Nikpayam O, Angoorani P, Hedayati M. The barberry juice effects on metabolic factors and oxidative stress in patients with type 2 diabetes: A randomized clinical trial. Complement Ther Clin Pract. 2018;31:170-174. doi:https://doi.org/10.1016/j.ctcp.2018.01.009 google scholar
  30. Li Z, Ye CY, Zhao TY, Yang L. Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population. BMC Public Health. 2020;20(1):1024. doi:https://doi.org/10.1186/s12889-020-09130-5 google scholar
  31. Liu N, Yu W, Liu X, et al. Glycation of paraoxonase 1 by high glucose instigates endoplasmic reticulum stress to induce endothelial dysfunction in vivo. Sci Rep. 2017;7(1):45827. doi:https://doi.org/10.1038/srep45827 google scholar
  32. Mackness M, Mackness B, Durrington P, et al. Low paraoxonase activity predicts coronary events in the caerphilly prospective Study. Circulation. 2003;107(22):2775-2779. doi:https://doi.org/10.1161/01.CIR.0000070954.00271.13 google scholar
  33. Mackness M, Mackness B. Promiscuous activities and multiple physiological roles: human paraoxonase1 (PON1) gene structure and expression. Gene. 2015;567(1):12-21. doi:https://doi.org/10.1016/j.gene.2015.04.088 google scholar
  34. Mackness M, Sozmen EY. A critical review on human serum paraoxonase1 in the literature: truths and misconceptions. Turk J Biochem. 2021;46(1):38-46. doi:https://doi.org/10.1515/tjb-2020-0186 google scholar
  35. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin- dependent diabetes mellitus. Atherosclerosis. 1991;86(2-3):193-199. doi:https:// doi.org/10.1016/0021-9150(91)90215-O google scholar
  36. Mahrooz A, Variji A, Shokri Y, et al. Combined utility of myeloperoxidase and paraoxonase 1 as two crucial HDL-associated enzymes in coronary artery disease. Atherosclerosis. 2019;280:71-73. google scholar
  37. Mahrooz A. Pharmacological interactions of paraoxonase 1 (PON1): A HDL- bound anti-atherogenic enzyme. Curr Clin Pharmacol. 2016;11(4):259-264. google scholar
  38. Masoumi P, Zargari M, Sharafeddin F, et al. The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity accounts for part of the altered antioxidant status in type 2 diabetes. Exp Biol Med. 2016;241(14):1489-1496. doi:https://doi.org/10.1177/1535370216641786 google scholar
  39. Mitra S, Kshatriya GK. Genetic variation at Q192R and L55M polymorphisms in PON1. Environ Toxicol Pharmacol. 2016; 45:251-256. doi:https://doi.org/10.1016/j. etap.2016.06.004 google scholar
  40. Oguntibeju OO. Oxidative stress and inflammation: Examining the links in type 2 diabetes mellitus. Int J Physiol Pathophysiol Pharmacol. 2019;11(3):45-53. google scholar
  41. Omrani MD, Shokri F, Ghaedi H, et al. Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients. Int J Mol Cell Med. 2016;5(1):1-7. google scholar
  42. Otocka-Kmiecik A. Effect of carotenoids on paraoxonase-1 activity and gene expression. Nutrients. 2022;14(14):2842. doi:https://doi.org/10.3390/nu14142842 google scholar
  43. Paragh G, Kalmar T, Seres I, et al. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab. 2005;31(6):574-580. doi:https://doi.org/10.1016/S1262-3636(07)70233-1 google scholar
  44. Pardo-Oviedo JM, Corredor-Orlandelli D, Sambrano-Cosparrado S, et al. Association between paraoxonase1 P.Q192R polymorphism and coronary artery disease susceptibility in the Colombian population. Vasc Health Risk Manag. 2021;17:689-699. doi:https://doi.org/10.2147/VHRM.S330766 google scholar
  45. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) represents a more potent antioxidant and stimulant of macrophage cholesterol efflux when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis. 2006;187(1):74-81. doi:https://doi.org/10.1016/j.atherosclerosis. 2005.08.026 google scholar
  46. Santos FG, Becker MK, Corrêa VS, et al. The effect of the paraoxonase 1 (PON1) T (−107) C polymorphism on serum PON1 activity in women is dependent on fatty acid intake. Nutrition Res. 2016;36(1):9-15. doi:https://doi.org/10.1016/j.nutres. 2015.10.008 google scholar
  47. Ściskalska M, Lewoń-Mrozek D, Kurzynoga J, et al. Molecular structure of paraoxonase1 and its modifications in relation to enzyme activity and biological functions—a comprehensive review. Int J Mol Sci. 2024;25(23):13129. doi:https://doi.org/10.3390/ijms252313129 google scholar
  48. Shah PK. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol. 2010;25(6):603-608 doi:10.1097/ HCO.0b013e32833f0382 google scholar
  49. Shen H, Robertson LW, Ludewig G. Regulatory effects of dioxinlike and nondioxin like PCBs and other AHR ligands on antioxidant enzymes paraoxonase 1/2/3. Environ Sci Pollut Res Int. 2016;23(3):2108-2118. doi:https:// doi.org/10.1007/s11356-015-4722-1 google scholar
  50. Silman I, Harel M, Aharoni A, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11(5):412-419. doi:https://doi.org/10.1038/nsmb767 google scholar
  51. Singh S, Kriti M, Sarma DK, Verma V, Nagpal R, Mohania D, Tiwari R, Kumar M. Deciphering the complex interplay of risk factors in type 2 diabetes mellitus: A comprehensive review. Metabolism Open. 2024;22:100287. doi:https://doi.org/ 10.1016/j.metop.2024.100287 google scholar
  52. Stroehla BC, Eichner JE, Dunn ST, et al. Apolipoprotein E polymorphism and cardiovascular disease: A huge review. Am J Epidemiol. 2002;155(6):487-495. doi:https://doi.org/%2010.1093/aje/155.6.487 google scholar
  53. Styrkarsdottir U, Grant SF, Thorleifsson G, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320-323. google scholar
  54. Szuchman-Sapir A, Gilad D, Atiya S, et al. Paraoxonase 1 in endothelial cells impairs vasodilation induced by arachidonic acid lactone metabolite. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(3):386-393. doi:https://doi.org/10. 1016/j.bbalip.2018.12.008 google scholar
  55. Talerverčič A, Goličnik M, Bavec A. The structure and function of paraoxonase1 and its comparison to paraoxonase2 and 3. Molecules. 2020;25(24):5980. doi:https://doi.org/10.3390/molecules25245980 google scholar
  56. Tuomi T, Altshuler D, Hirschhorn JN, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26(1):76-80. doi:10.1038/79216 google scholar
  57. Ukoli FA, Kamboh MI, Bunker CH, et al. Genetic association of five apolipoprotein polymorphisms with serum lipoprotein-lipid levels in African Blacks. Genet Epidemiol. 1999;16(2):205-222. doihttps://doi.org/10.1002/(SICI) 1098-2272(1999)16:2%3C205::AID-GEPI7%3E3.0.CO;2-P google scholar
  58. Wamique M, Ali W, Reddy DH, Vishwakarma P, Waseem M. A case control study on HDL associated PON1 enzyme level in Northern Indian type 2 diabetes mellitus patients. Diabetes Metab Syndr. 2018;12(6):843-847. doi:https://doi.org/ 10.1016/j.dsx.2018.03.005 google scholar
  59. Xiang DX, Luo JQ, Ren H, et al. European versus Asian differences in associations between paraoxonase1 genetic polymorphisms and susceptibility to type 2 diabetes mellitus. J Cell Mol Med. 2018;22(3):1720-1732. doi:https://doi.org/10. 1111/jcmm.13453 google scholar
  60. Zargari M, Maadi N, Rezapour M, Bagheri A, Fallahpour S, Nosrati M, Mahrooz A. The regulatory variant-108C/T in the promoter of paraoxonase 1 (PON1) gene has a more important role in regulating PON1 activity compared to rs3735590 in 3ʹ-UTR in patients with coronary artery disease. Advanced Biomed Res. 2024;13(1):38. doi:https://doi.org/10.4103/abr.abr_391_22 google scholar
  61. Zinman B, Hegele RA, Connelly PW, et al. Paraoxonase2 G148 variant in an Aboriginal Canadian girl with non–insulin-dependent diabetes. Lancet. 1997;350(9080):785. doi:https://doi.org/10.1016/S0140-6736(05)62570-6 google scholar